ArticleTranslational andrology and urology2025
Leveraging hypoxia-related genes signature for predicting the prognosis of bladder cancer.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypoxia is common in solid tumors, facilitating tumor growth and treatment resistance, and is crucial for optimizing patient outcomes, but research on the mechanism of hypoxia in bladder cancer (BC) remains limited. This study aims to explore the functional role of hypoxia-related genes (HRGs) in BC. Methods: The HRGs were obtained from GeneCards, and the hypoxia score in BC patients was evaluated by single-sample gene set enrichment analysis (ssGSEA). The prognostic risk model was constructed using differentially expressed prognostic HRGs, and assessed via time-dependent receiver operating characteristic (ROC) curves, Kaplan-Meier (KM) curve, and nomogram analysis. Differential features between high- and low-risk groups were analyzed, including clinical characteristics, biological functions, mutation profiles, immune infiltration, and drug sensitivity. We measured the expression of hub genes Results: The hypoxia score system was proven effective in BC diagnosis and prognostic prediction based on ROC and KM analyses. The prognostic risk model was constructed with Conclusions: We developed a novel prognostic risk model as an independent predictor for BC patients, which offers insights into immune microenvironment and carcinogenesis mechanisms of BC. Analyzing mutation patterns, drug sensitivities, and the developmental trajectories of genes within this model would be helpful for refining therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.